301 related articles for article (PubMed ID: 22761704)
1. NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer.
Ademuyiwa FO; Bshara W; Attwood K; Morrison C; Edge SB; Karpf AR; James SA; Ambrosone CB; O'Connor TL; Levine EG; Miliotto A; Ritter E; Ritter G; Gnjatic S; Odunsi K
PLoS One; 2012; 7(6):e38783. PubMed ID: 22761704
[TBL] [Abstract][Full Text] [Related]
2. NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors.
Sugita Y; Wada H; Fujita S; Nakata T; Sato S; Noguchi Y; Jungbluth AA; Yamaguchi M; Chen YT; Stockert E; Gnjatic S; Williamson B; Scanlan MJ; Ono T; Sakita I; Yasui M; Miyoshi Y; Tamaki Y; Matsuura N; Noguchi S; Old LJ; Nakayama E; Monden M
Cancer Res; 2004 Mar; 64(6):2199-204. PubMed ID: 15026363
[TBL] [Abstract][Full Text] [Related]
3. Expression of NY-ESO-1 in Triple-Negative Breast Cancer Is Associated with Tumor-Infiltrating Lymphocytes and a Good Prognosis.
Lee HJ; Kim JY; Song IH; Park IA; Yu JH; Gong G
Oncology; 2015; 89(6):337-44. PubMed ID: 26413775
[TBL] [Abstract][Full Text] [Related]
4. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
[TBL] [Abstract][Full Text] [Related]
5. Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?
Tessari A; Pilla L; Silvia D; Duca M; Paolini B; Carcangiu ML; Mariani L; de Braud FG; Cresta S
Breast; 2018 Dec; 42():68-73. PubMed ID: 30189381
[TBL] [Abstract][Full Text] [Related]
6. Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers.
Chen YT; Ross DS; Chiu R; Zhou XK; Chen YY; Lee P; Hoda SA; Simpson AJ; Old LJ; Caballero O; Neville AM
PLoS One; 2011 Mar; 6(3):e17876. PubMed ID: 21437249
[TBL] [Abstract][Full Text] [Related]
7. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.
Tang D; Xu S; Zhang Q; Zhao W
Med Oncol; 2012 Jun; 29(2):526-33. PubMed ID: 21519872
[TBL] [Abstract][Full Text] [Related]
8. Expression of tumor-associated antigens in breast cancer subtypes.
Curigliano G; Bagnardi V; Ghioni M; Louahed J; Brichard V; Lehmann FF; Marra A; Trapani D; Criscitiello C; Viale G
Breast; 2020 Feb; 49():202-209. PubMed ID: 31869767
[TBL] [Abstract][Full Text] [Related]
9. Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer.
Mischo A; Kubuschok B; Ertan K; Preuss KD; Romeike B; Regitz E; Schormann C; de Bruijn D; Wadle A; Neumann F; Schmidt W; Renner C; Pfreundschuh M
Int J Cancer; 2006 Feb; 118(3):696-703. PubMed ID: 16094643
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological and prognostic characteristics of triple- negative breast cancer (TNBC) in Chinese patients: a retrospective study.
Li CY; Zhang S; Zhang XB; Wang P; Hou GF; Zhang J
Asian Pac J Cancer Prev; 2013; 14(6):3779-84. PubMed ID: 23886182
[TBL] [Abstract][Full Text] [Related]
11. NY-ESO-1 protein expression in primary breast carcinoma and metastases: correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration.
Theurillat JP; Ingold F; Frei C; Zippelius A; Varga Z; Seifert B; Chen YT; Jäger D; Knuth A; Moch H
Int J Cancer; 2007 Jun; 120(11):2411-7. PubMed ID: 17294444
[TBL] [Abstract][Full Text] [Related]
12. Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy.
Hamaï A; Duperrier-Amouriaux K; Pignon P; Raimbaud I; Memeo L; Colarossi C; Canzonieri V; Perin T; Classe JM; Campone M; Jézéquel P; Campion L; Ayyoub M; Valmori D
PLoS One; 2011; 6(6):e21129. PubMed ID: 21747904
[TBL] [Abstract][Full Text] [Related]
13. Cancer-testis antigen expression in triple-negative breast cancer.
Curigliano G; Viale G; Ghioni M; Jungbluth AA; Bagnardi V; Spagnoli GC; Neville AM; Nolè F; Rotmensz N; Goldhirsch A
Ann Oncol; 2011 Jan; 22(1):98-103. PubMed ID: 20610479
[TBL] [Abstract][Full Text] [Related]
14. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens.
Stockert E; Jäger E; Chen YT; Scanlan MJ; Gout I; Karbach J; Arand M; Knuth A; Old LJ
J Exp Med; 1998 Apr; 187(8):1349-54. PubMed ID: 9547346
[TBL] [Abstract][Full Text] [Related]
15. Ki67 Frequency in Breast Cancers without Axillary Lymph Node Involvement and its Relation with Disease-free Survival.
Shandiz FH; Shabahang H; Afzaljavan F; Sharifi N; Tavasoli A; Afzalaghaee M; Roshanzamir E; Pasdar A
Asian Pac J Cancer Prev; 2016; 17(3):1347-50. PubMed ID: 27039770
[TBL] [Abstract][Full Text] [Related]
16. NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer.
Szender JB; Papanicolau-Sengos A; Eng KH; Miliotto AJ; Lugade AA; Gnjatic S; Matsuzaki J; Morrison CD; Odunsi K
Gynecol Oncol; 2017 Jun; 145(3):420-425. PubMed ID: 28392127
[TBL] [Abstract][Full Text] [Related]
17. Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.
Linderholm B; Bergqvist J; Hellborg H; Johansson U; Linderholm M; von Schoultz E; Elmberger G; Skoog L; Bergh J
Med Oncol; 2009 Dec; 26(4):480-90. PubMed ID: 19130322
[TBL] [Abstract][Full Text] [Related]
18. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma.
Korangy F; Ormandy LA; Bleck JS; Klempnauer J; Wilkens L; Manns MP; Greten TF
Clin Cancer Res; 2004 Jul; 10(13):4332-41. PubMed ID: 15240519
[TBL] [Abstract][Full Text] [Related]
19. NY-ESO-1 expression and immunogenicity in esophageal cancer.
Fujita S; Wada H; Jungbluth AA; Sato S; Nakata T; Noguchi Y; Doki Y; Yasui M; Sugita Y; Yasuda T; Yano M; Ono T; Chen YT; Higashiyama M; Gnjatic S; Old LJ; Nakayama E; Monden M
Clin Cancer Res; 2004 Oct; 10(19):6551-8. PubMed ID: 15475443
[TBL] [Abstract][Full Text] [Related]
20. Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence.
Brown TA; Mittendorf EA; Hale DF; Myers JW; Peace KM; Jackson DO; Greene JM; Vreeland TJ; Clifton GT; Ardavanis A; Litton JK; Shumway NM; Symanowski J; Murray JL; Ponniah S; Anastasopoulou EA; Pistamaltzian NF; Baxevanis CN; Perez SA; Papamichail M; Peoples GE
Breast Cancer Res Treat; 2020 Jun; 181(2):391-401. PubMed ID: 32323103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]